Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study

[1]  P. Zhang,et al.  Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort , 2023, Frontiers in Immunology.

[2]  Yanfeng Hu,et al.  Safety and short-term outcomes of laparoscopic surgery for advanced gastric cancer after neoadjuvant immunotherapy: A retrospective cohort study , 2022, Frontiers in Immunology.

[3]  P. Tighe,et al.  Outcomes of transversus abdominis plane block in ventral hernia repair: A propensity score matching analysis using a national database , 2022, International Journal of Abdominal Wall and Hernia Surgery.

[4]  P. Zhang,et al.  Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial , 2022, Frontiers in Oncology.

[5]  N. Girard,et al.  Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.

[6]  Zhongqi Li,et al.  Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study , 2022, Journal for ImmunoTherapy of Cancer.

[7]  Chang-ming Huang,et al.  Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion , 2022, Frontiers in Immunology.

[8]  Baorui Liu,et al.  Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges , 2021, Cancers.

[9]  J. Ji,et al.  Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised c , 2021, The Lancet. Oncology.

[10]  Jae Hyun Kim,et al.  PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Ajani,et al.  First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial , 2021, The Lancet.

[12]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[13]  L. Zitvogel,et al.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors , 2020, Nature Reviews Clinical Oncology.

[14]  W. Xu,et al.  Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial. , 2020, European journal of cancer.

[15]  Ying-bin Liu,et al.  Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO‐CLASSIC Study , 2019, The oncologist.

[16]  M. Egger,et al.  Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial , 2019, The Lancet.

[17]  J. Ji,et al.  Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II−III randomized trial , 2018, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[18]  Yuan Ji,et al.  Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis , 2018, BMC Cancer.

[19]  J. Ajani,et al.  Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved , 2018, Annals of Surgical Oncology.

[20]  Byung-Hoon Min,et al.  Long-Term Outcome of Endoscopic Resection vs. Surgery for Early Gastric Cancer: A Non-inferiority-Matched Cohort Study , 2016, The American Journal of Gastroenterology.

[21]  J. Cheong,et al.  Surgical Complications in Gastric Cancer Patients Preoperatively Treated with Chemotherapy: Their Risk Factors and Clinical Relevance , 2012, Annals of Surgical Oncology.

[22]  J. Pignon,et al.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Boccia,et al.  Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[25]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[26]  H. Höfler,et al.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy , 2003, Cancer.

[27]  J. Sanabria,et al.  Proposed classification of complications of surgery with examples of utility in cholecystectomy. , 1992, Surgery.

[28]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.